Breakdown | |||
TTM | Mar 2024 | Mar 2023 | Mar 2022 |
---|---|---|---|
Income Statement | Total Revenue | ||
0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
-89.00K | -81.00K | 0.00 | 0.00 | EBIT |
-10.75M | -7.47M | -1.99M | -13.59M | EBITDA |
-13.27M | -15.27M | 0.00 | 752.45K | Net Income Common Stockholders |
-13.63M | -15.43M | -1.99M | -13.33M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||
11.82M | 8.61M | 864.62K | 2.04M | Total Assets |
11.95M | 9.41M | 864.62K | 2.05M | Total Debt |
1.13M | 1.00M | 0.00 | 0.00 | Net Debt |
-10.69M | -7.61M | -864.62K | -2.04M | Total Liabilities |
2.25M | 1.78M | 220.59K | 93.24K | Stockholders Equity |
9.71M | 7.63M | 644.03K | 1.96M |
Cash Flow | Free Cash Flow | ||
-8.06M | -6.67M | -1.85M | -387.31K | Operating Cash Flow |
-8.04M | -6.65M | -1.85M | -387.31K | Investing Cash Flow |
-29.00K | -19.00K | 0.00 | 0.00 | Financing Cash Flow |
18.65M | 14.41M | 675.00K | 2.43M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $177.44B | 77.39 | 15.62% | ― | 17.24% | 27.76% | |
70 Outperform | $2.26B | 66.60 | 19.39% | ― | 82.74% | ― | |
69 Neutral | $4.74B | 91.13 | 8.48% | ― | 28.49% | ― | |
54 Neutral | $4.10B | -18.87 | -17.06% | 5.92% | 25.76% | -79.79% | |
51 Neutral | $869.61M | 55.81 | -5.16% | ― | -2.64% | -193.31% | |
46 Neutral | $73.29M | ― | -51.63% | ― | 11.26% | -14.21% | |
37 Underperform | $4.26M | ― | -662.74% | ― | ― | -10.29% |
On January 22, 2025, Autonomix Medical, Inc.’s CEO, Brad Hauser, participated in the Virtual Investor Closing Bell Series. The event was webcast live, with a replay available for 90 days, and marked a significant engagement with investors, offering insights into the company’s positioning and expectations. The conference presentation included forward-looking statements highlighting risks and uncertainties, emphasizing the need for stakeholders to review cautionary statements and disclosures filed with the SEC.